Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

U.S. markets have been on a historic bull run since the end of the pandemic. However, many investors may start to be wary.

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript November 7, 2024 Cassava Sciences, Inc. beats earnings ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.

Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

College of Agriculture and Food Technology (CoAF) in Lindi Region is poised to revolutionise agriculture in southern Tanzania ...

Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash ...